• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Adrenocortical Carcinoma Adrenal Tumor - Pipeline Review, Q2 2011 - Product Image

Adrenocortical Carcinoma Adrenal Tumor - Pipeline Review, Q2 2011

  • ID: 1801416
  • April 2011
  • 65 pages
  • Global Markets Direct

Adrenocortical Carcinoma Adrenal Tumor - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Adrenocortical Carcinoma Adrenal Tumor - Pipeline Review, Q2 2011', provides an overview of the Adrenocortical Carcinoma Adrenal Tumor therapeutic pipeline. This report provides information on the therapeutic development for Adrenocortical Carcinoma Adrenal Tumor, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Adrenocortical Carcinoma Adrenal Tumor. 'Adrenocortical Carcinoma Adrenal Tumor - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Adrenocortical READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Adrenocortical Carcinoma Adrenal Tumor Overview
Therapeutics Development
An Overview of Pipeline Products for Adrenocortical Carcinoma Adrenal Tumor
Adrenocortical Carcinoma Adrenal Tumor Therapeutics under Development by Companies
Adrenocortical Carcinoma Adrenal Tumor Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Adrenocortical Carcinoma Adrenal Tumor Therapeutics - Products under Development by Companies
Adrenocortical Carcinoma Adrenal Tumor Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Adrenocortical Carcinoma Adrenal Tumor Therapeutics Development
Astellas Pharma Inc.
Pfizer Inc.
BTG International Ltd
Neotropix, Inc.
AstraZeneca AB
Adrenocortical Carcinoma Adrenal Tumor - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Axitinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OSI-906 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NTX-010 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
R935788 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RAD001 + Vatalanib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Iressa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OncoGel + Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Doxorubicin + Tamoxifen + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zactima + Velcade - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oxaliplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Suramin + Hydrocortisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sutent - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RAD001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bevacizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Streptozocin + Mitotane - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sorafenib + Paclitaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Pegfilgrastim + Cisplatin + Doxorubicin + Etoposide + Mitotane - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Doxorubicin + Vincristine + Etoposide + Mitotane - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temsirolimus + Vinorelbine Ditartrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
doxorubicin hydrochloride + etoposide + mitotane + tariquidar + vincristine sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sunitinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cixutumumab + temsirolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AT-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Adrenocortical Carcinoma Adrenal Tumor Therapeutics – Drug Profile Updates
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Adrenocortical Carcinoma Adrenal Tumor, Q2 2011
Products under Development for Adrenocortical Carcinoma Adrenal Tumor – Comparative Analysis, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Comparative Analysis by Late Stage Development, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Comparative Analysis by Early Clinical Stage Development, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Astellas Pharma Inc., 2011
Pfizer Inc., 2011
BTG International Ltd, 2011
Neotropix, Inc., 2011
AstraZeneca AB, 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Adrenocortical Carcinoma Adrenal Tumor Therapeutics – Drug Profile Updates

List of Figures
Number of Products under Development for Adrenocortical Carcinoma Adrenal Tumor, Q2 2011
Products under Development for Adrenocortical Carcinoma Adrenal Tumor – Comparative Analysis, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Late Stage Products, Q2 2011
Mid Clinical Stage Products, Q2 2011
Early Clinical Stage Products, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products, Q2 2011
Assessment by Route of Administration, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Assessment by Stage and Molecule Type, Q2 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos